Barclays Lowers RadNet Price Target, Keeps Overweight Rating
Barclays lowered its price target on RadNet (RDNT) to $65 from $70 but reiterated an Overweight rating, citing continued outperformance in advanced imaging volume and pricing.
Barclays has lowered its price target on RadNet (NASDAQ: RDNT) to $65 from $70, while maintaining an Overweight rating on the stock. The revision comes from analyst Andrew Mok, who noted that RadNet's imaging business continues to outperform its competitor Lumexa in advanced volume growth and pricing. The new target implies a modest upside from recent trading levels, though it reflects a more cautious near-term valuation. RadNet operates a network of outpatient imaging centers across the United States, providing services such as MRI, CT, and PET scans, which are critical for diagnosing a wide range of medical conditions.
For traders, the price target cut may signal a tempered near-term outlook, but the reiterated Overweight rating suggests confidence in RadNet's fundamental strength. The company's imaging segment, which drives a significant portion of revenue, has shown resilience and competitive advantages. In the healthcare sector, imaging volumes are often tied to broader utilization trends, and RadNet's ability to outperform peers like Lumexa indicates strong operational execution. Investors can track live RadNet stock prices and charts on NowPrice to monitor market reaction to this analyst update. The stock has been volatile in recent months, reflecting both sector-wide pressures and company-specific developments.
Looking ahead, RadNet's recent joint venture with Saint Alphonsus Health System and the acquisition of a majority stake in Intermountain Medical Imaging expand its footprint in Idaho. These strategic moves could support future growth, but traders should watch for upcoming quarterly results and any shifts in imaging volume trends that might influence analyst sentiment further. Additionally, the broader healthcare policy environment, including potential changes in Medicare reimbursement rates, could impact RadNet's margins. With the company's next earnings report expected in the coming weeks, investors will be keen to see if the imaging business can sustain its momentum and justify the current valuation.